Evicenter

Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer

Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Enhertu (opens in a new tab)
Questions
30
Last updated

All products

30 questions · 11 sources

Indication5 questions · 5 sources

Clinical trials11 questions · 5 sources

Safety12 questions · 4 sources

Dosing and administration1 question · 2 sources

Guidelines1 question · 1 source